CDNA · CareDx, Inc.

Current Thesis

CareDx’s reimbursement repricing now depends on the next quarterly report sustaining its raised revenue outlook; a weekly close below $44 would invalidate the price structure supporting that thesis. The July policy decision has passed its 2026-08-30 effective date, while Canaccord Genuity’s 2026-09-02 coverage initiation supplies fresh analyst attention. Canaccord assigned a $65 price target, extending the coverage sequence beyond BTIG’s 2026-08-06 revision. Canaccord initiation, reported by The Fly.

The distinction is between attention and operating confirmation. CareDx raised its full-year 2026 revenue guidance to $490–500 million on 2026-07-30; September’s analyst initiation does not establish that the company has exceeded that outlook. CareDx’s July results. As an inference, the narrative is maturing — the 2026-07-16 reimbursement decision and July results are established evidence, and the 2026-09-11 adjusted close of $50.26 remains below the supplied $52.36 annual high despite new coverage.

Bullish and bearish views on CareDx, Inc.

The model's bull view on CareDx, Inc. (CDNA), in brief: The operating outlook was raised. On 2026-07-30, CareDx increased full-year 2026 revenue guidance from $447–465 million to $490–500 million and adjusted earnings before interest, taxes, depreciation and amortization guidance from $43–57 million to $66–78 million. These are… The bear view: Revenue growth exceeded test growth. CareDx’s 2026-07-30 release reported second-quarter testing-services revenue of $100 million, up 61% year over year, against approximately 58,000 tests, up 17%. It also disclosed $16 million of prior-period revenue. The reported revenue… Both cases follow in full.

Bull Case

• The operating outlook was raised. On 2026-07-30, CareDx increased full-year 2026 revenue guidance from $447–465 million to $490–500 million and adjusted earnings before interest, taxes, depreciation and amortization guidance from $43–57 million to $66–78 million. These are management forecasts, with a subsequent reduction below $490 million breaking the revenue case. Company results.
• Analyst attention resumed in September. Canaccord initiated coverage with a $65 price target on 2026-09-02. The initiation extends the dated coverage record; it does not measure additional institutional demand. The Fly report.
• The August reference remains below price. The adjusted close was $50.26 on 2026-09-11, above the $48.61 close recorded on 2026-08-21. This supports an inference that the repricing remains intact, subject to the weekly $44 invalidation condition.

Bear Case

• Revenue growth exceeded test growth. CareDx’s 2026-07-30 release reported second-quarter testing-services revenue of $100 million, up 61% year over year, against approximately 58,000 tests, up 17%. It also disclosed $16 million of prior-period revenue. The reported revenue growth therefore does not establish an equivalent rate of underlying testing demand. Company results.
• Historical insider supply was documented. Peter Maag’s Form 144 filed on 2026-08-12 disclosed sales during the preceding three months; a further notice was filed on 2026-08-17. These are dated supply observations. They do not establish continued September selling, and notices of proposed sales are not confirmation of execution.
• The advance lacks participation measurements. The supplied adjusted series shows a three-month price increase of 118.8% through 2026-09-11. Trading-volume, fund-flow and retail-sentiment measurements are missing, so the advance cannot establish either broad participation or crowded ownership.

Setup & Price Structure

The 2026-09-11 adjusted close was $50.26, 4.0% below the supplied 52-week high of $52.36. The 14-period relative strength index was 56.3 on that date. A moving-average value is unavailable, so no distance above a rising average can be established.

The $48.61 close of 2026-08-21 remains a nearer reference within the August $46.69–$48.61 band identified in the 2026-08-30 coverage. The weekly $44 threshold remains the published thesis boundary below that band; it is an analytical condition, not a newly measured support level. A weekly close above the supplied $52.36 high would confirm renewed price expansion, whereas a weekly close below $44 would invalidate this continuation case.

Catalyst Calendar (next 30 days)

As checked on 2026-09-13, CareDx’s investor calendar lists no upcoming events. No confirmed earnings or conference date is available for 2026-09-13 through 2026-10-13. CareDx events calendar.

• 2026-09-30 — Quarter-end measurement date. Following the Lab Products divestiture on 2026-06-30 and Naveris acquisition on 2026-07-01, the September quarter covers the changed business mix. Quarter end is not a scheduled results announcement and does not itself resolve performance against the July guidance.

The next quarterly results are the operating test, but their publication date is unconfirmed. The earlier estimated September conference appearance has no company-calendar confirmation and is not a dated catalyst.

What Would Change Our Mind

Loss of the August repricing structure would break the market case: a weekly close below $44 would place the shares below the $46.69–$48.61 band documented in the 2026-08-30 note. Separately, a reduction of full-year 2026 revenue guidance below the $490 million lower bound announced on 2026-07-30 would break the operating case.

A published MolDX billing or coding restriction narrowing surveillance coverage after the 2026-08-30 effective date would undermine the policy premise established by the 2026-07-16 decision. Confirmation requires an actual contractor publication or company disclosure; silence does not establish unrestricted reimbursement.

The positive case would be demonstrated by the next quarterly report maintaining or raising the July revenue range, together with a weekly close above $52.36 before the $44 boundary is breached. This is a conditional test, not evidence that either outcome has occurred.

Correlation Notes

This remains a single-company reimbursement and earnings case. The dated evidence centers on the 2026-07-16 policy decision, the 2026-07-30 guidance increase and the 2026-09-02 analyst initiation; no matched peer-return series is available through 2026-09-11. These observations are too few to support a correlation claim or an inference that a wider diagnostics-sector move explains the advance.